indolent B-cell non-Hodgkin lymphoma
diseaseOn this page
Also known as B cell lymphoma, indolentindolent B cell lymphomaindolent B-cell NHL
Summary
indolent B-cell non-Hodgkin lymphoma (MONDO:0017594) is a cancer (an umbrella term covering 6 Mondo subtypes) and 21 clinical trials. Top therapeutic interventions include rituximab, acalabrutinib, and epcoritamab. A subtype of B-cell non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: Unknown (Worldwide)
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | indolent B-cell non-Hodgkin lymphoma |
| Mondo ID | MONDO:0017594 |
| Orphanet | 300842 |
| NCIT | C171299 |
| UMLS | C5419078 |
| MedGen | 1741600 |
| GARD | 0021244 |
| Is cancer (heuristic) | yes |
Also known as: B cell lymphoma, indolent · indolent B cell lymphoma · indolent B-cell NHL
Disease family
This is a subtype of B-cell non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › B-cell non-Hodgkin lymphoma › indolent B-cell non-Hodgkin lymphoma
Related subtypes (4): B-cell acute lymphoblastic leukemia, aggressive B-cell non-Hodgkin lymphoma, plasma cell leukemia, central nervous system non-hodgkin lymphoma
Subtypes (6): B-cell chronic lymphocytic leukemia, indolent primary cutaneous B-cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma without IgM production, follicular lymphoma, Waldenstrom macroglobulinemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE1 | 6 |
| PHASE1/PHASE2 | 4 |
| Not specified | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06343935 | PHASE4 | UNKNOWN | A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma |
| NCT01289223 | PHASE3 | TERMINATED | A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin’s Lymphoma (NHL) Refractory to Rituximab. |
| NCT03571568 | PHASE1/PHASE2 | RECRUITING | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL |
| NCT03625037 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma |
| NCT05025800 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma |
| NCT06386315 | PHASE2 | RECRUITING | Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma |
| NCT06461182 | PHASE2 | RECRUITING | Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma |
| NCT07098364 | PHASE1/PHASE2 | RECRUITING | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma |
| NCT00895661 | PHASE2 | COMPLETED | High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas |
| NCT02836925 | PHASE2 | COMPLETED | Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection |
| NCT03498612 | PHASE2 | TERMINATED | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases |
| NCT05169658 | PHASE2 | COMPLETED | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma |
| NCT05621096 | PHASE1 | ACTIVE_NOT_RECRUITING | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma |
| NCT05665062 | PHASE1 | ACTIVE_NOT_RECRUITING | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies |
| NCT06544265 | PHASE1 | RECRUITING | SynKIR-310 for Relapsed/Refractory B-NHL |
| NCT01805375 | PHASE1 | COMPLETED | A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies |
| NCT03019666 | PHASE1 | COMPLETED | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL |
| NCT04578600 | PHASE1 | COMPLETED | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma |
| NCT02846935 | EARLY_PHASE1 | COMPLETED | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies |
| NCT06822829 | Not specified | RECRUITING | Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma |
| NCT05803395 | Not specified | UNKNOWN | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RITUXIMAB | 4 | 3 |
| ACALABRUTINIB | 4 | 1 |
| EPCORITAMAB | 4 | 1 |
| LEDIPASVIR | 4 | 1 |
| MOSUNETUZUMAB | 4 | 1 |
| POLATUZUMAB VEDOTIN | 4 | 1 |
| VELPATASVIR | 4 | 1 |
| LISOCABTAGENE MARALEUCEL | 3 | 1 |
| LINPERLISIB | 2 | 1 |
| TETRAHYDROURIDINE | 2 | 1 |
| VEVOCTADEKIN | 2 | 1 |
| BI-1206 | 1 | 1 |
| CHEMBL4747506 | 0 | 1 |
| CHEMBL5187554 | 0 | 1 |
| CHEMBL5276925 | 0 | 1 |